NASDAQ: SMMT
Summit Therapeutics Inc Stock

$19.89-0.35 (-1.73%)
Updated Mar 26, 2025
SMMT Price
$19.89
Fair Value Price
$0.18
Market Cap
$14.67B
52 Week Low
$2.10
52 Week High
$33.89
P/E
-6,630x
P/B
37.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$221.32M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$142M
Beta
0.52
Next Earnings
Apr 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A

SMMT Overview

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine SMMT's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
SMMT
Ranked
#180 of 479

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important SMMT news, forecast changes, insider trades & much more!

SMMT News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SMMT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SMMT ($19.89) is overvalued by 11,236.95% relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SMMT ($19.89) is not significantly undervalued (11,236.95%) relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SMMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SMMT due diligence checks available for Premium users.

Valuation

SMMT fair value

Fair Value of SMMT stock based on Discounted Cash Flow (DCF)

Price
$19.89
Fair Value
$0.18
Overvalued by
11,236.95%
SMMT ($19.89) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SMMT ($19.89) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SMMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SMMT price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-6,630x
Industry
-115.59x
Market
31.65x

SMMT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
37.74x
Industry
4.53x
SMMT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SMMT's financial health

Profit margin

Revenue
$0.0
Net Income
-$61.2M
Profit Margin
0%
SMMT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$435.6M
Liabilities
$46.8M
Debt to equity
0.12
SMMT's short-term assets ($423.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SMMT's short-term assets ($423.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SMMT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SMMT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$48.7M
Investing
$83.5M
Financing
-$23.6M
SMMT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SMMT vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
SMMTC$14.67B-1.73%-6,630.00x37.74x
UTHRB$13.96B-1.87%11.76x2.17x
INSMC$13.86B-2.51%-13.75x48.56x
BMRNA$13.64B-0.07%31.77x2.41x
GMABB$12.99B+2.94%11.49x2.53x

Summit Therapeutics Stock FAQ

What is Summit Therapeutics's quote symbol?

(NASDAQ: SMMT) Summit Therapeutics trades on the NASDAQ under the ticker symbol SMMT. Summit Therapeutics stock quotes can also be displayed as NASDAQ: SMMT.

If you're new to stock investing, here's how to buy Summit Therapeutics stock.

What is the 52 week high and low for Summit Therapeutics (NASDAQ: SMMT)?

(NASDAQ: SMMT) Summit Therapeutics's 52-week high was $33.89, and its 52-week low was $2.10. It is currently -41.31% from its 52-week high and 847.14% from its 52-week low.

How much is Summit Therapeutics stock worth today?

(NASDAQ: SMMT) Summit Therapeutics currently has 737,679,704 outstanding shares. With Summit Therapeutics stock trading at $19.89 per share, the total value of Summit Therapeutics stock (market capitalization) is $14.67B.

Summit Therapeutics stock was originally listed at a price of $10.19 in Mar 5, 2015. If you had invested in Summit Therapeutics stock at $10.19, your return over the last 10 years would have been 95.19%, for an annualized return of 6.92% (not including any dividends or dividend reinvestments).

How much is Summit Therapeutics's stock price per share?

(NASDAQ: SMMT) Summit Therapeutics stock price per share is $19.89 today (as of Mar 26, 2025).

What is Summit Therapeutics's Market Cap?

(NASDAQ: SMMT) Summit Therapeutics's market cap is $14.67B, as of Mar 27, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Summit Therapeutics's market cap is calculated by multiplying SMMT's current stock price of $19.89 by SMMT's total outstanding shares of 737,679,704.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.